Angitia Biopharmaceuticals' Phase 1/2 study demonstrated that AGA111, a recombinant human bone morphogenetic protein 6, achieved faster radiographic fusion and higher fusion success rates compared to placebo in spinal fusion procedures.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.